Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
Breder I, Cunha Breder J, Bonilha I, Munhoz DB, Medorima STK, Oliveira DC, do Carmo HR, Moreira C, Kontush A, Zimetti F, Zanotti I, Carvalho LSF, Nadruz W, Muscelli E, Quinaglia T, Sposito AC; EXCEED-BHS3 Trial Investigator.
Breder I, et al. Among authors: zimetti f.
Ther Adv Chronic Dis. 2020 Sep 28;11:2040622320959248. doi: 10.1177/2040622320959248. eCollection 2020.
Ther Adv Chronic Dis. 2020.
PMID: 33062236
Free PMC article.